New immunotherapy drug in cancer

Stage 3 & stage 4 cancer treatment in India. Immunotherapy treatment in cancer in India. Connect with +91 96 1588 1588 to know details. Immunotherapy treatment in Chennai, Kolkata, Delhi, Mumbai, Bengaluru & Mumbai.

Share This Post


Immune check point inhibitors are the class of drugs that fight with immune system of the body to fight cancerous cells. However, most patients do not respond to these therapy. There is a newer class of drug that targets two proteins involved in the suppressing the body’s immune response against tumors.

Phase I of clinical trials have shown some exciting results which were conducted in 19 patients suffering from cancer in with the molecule called M7824. These researchers are also undertaking trials suffering from pancreatic cancer and those infected with HPV.

There are many other trials and experiments being taken to treat and cure cancer more effectively in different research institutes. This drug with dual approach will be a boon in the treatment of cancer as with a single molecule multiple therapies are included.


For details on cancer treatment do call us at +91 96 1588 1588 or write to

Spread the love

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Development of CAR T Cell therapy in Korea
Cancer treatment in South Korea

Companies in Korea takes a step closer in developing home grown CAR T-Cell therapy

Due to high costs, treatments developed by multinational pharmaceutical corporations are difficult for Korean patients to access. As a result, Korean businesses have created and localised CAR-T treatments in an effort to address these issues. Many businesses have either begun developing CAR-T therapies or declared their intention to do so, including Curocell, Abclon, GC Cell, Ticaros, Helixmith, Toolgen, Cllengene, Eutilex, and Vaxcell Bio.

Spread the love
Blood cancer

Polatuzumab vedotin-piiq is approved by USFDA for previously untreated diffuse large B-cell lymphoma, not otherwise specified, and high-grade B-cell lymphoma

For adult patients with high-grade B-cell lymphoma (HGBL), not otherwise specified (NOS), or diffuse large B-cell lymphoma (DLBCL) who have not previously received treatment and who have an International Prognostic Index (IPI) score of 2 or higher, the Food and Drug Administration has approved polatuzumab vedotin-piiq (Polivy, Genentech, Inc.).

Spread the love

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

درمان سرطان در تركيه

Enquiry Form